An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2017
At a glance
- Drugs RG 7386 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Roche
- 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2017 Results (data cut off: 26 Apr 2017, n=32) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
- 20 Jul 2017 Planned End Date changed from 26 Sep 2017 to 31 Aug 2019.